Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria

BACKGROUND Chronic spontaneous urticaria (CSU) is frequently associated with psychiatric comorbidities. OBJECTIVE We aimed to determine if depressive symptoms were present in CSU patients who received omalizumab and depression scores got better treatment whether the presence of impaired responses. METHODS at least three injections included study. Changes Urticaria Activity Score (UAS), Quality Life Questionnaire (CU-Q2oL), Beck Depression Inventory (Beck-D) Control Test (UCT) compared before after treatment. RESULTS From 49 patients, 20 (40.8%) had baseline. After treatment, UAS7, CU-Q2oL, Beck-D decreased UCT-scores increased significantly (p < 0.001, for all). UCT lower baseline 3rd month following without (baseline median (interquartile range-IQR) 2.5 (1-5) vs 5 (2.5-6.5); p = 0.04 12 (9-13) 14 (12-16); 0.006, respectively). Omalizumab non-responders higher Beck-D-scores [18.5 (15.2-22) (6-22.5); 0.031]. The number among without. (40% 13.8%; 0.048). Only 6 scored as having treatment; these only one was an responder. CONCLUSIONS not provides symptom control but also improves psychological conditions patients. Coexistent comorbidities should be taken into account since might impair response.